Israel Cancer Research Fund Impact Statement 2022
2022 has been a mixed year for all of us. On the one hand, we have seen a return to in-person activities and are slowly…
Switching Between Intravenous and Oral P2Y12 Inhibition: Easier Said Than Done
Adequate suppression of platelet reactivity is necessary to mitigate early thrombotic events, including stent thrombosis, among patient undergoing percutaneous coronary intervention (PCI). Clinical trials conducted…
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet
Abstract Background There are no studies specifically designed to rule out a drug-drug interaction (DDI) when cangrelor is used among patients who have been pretreated with ticagrelor. Objectives…
Researchers Will Train AI to Diagnose Prostate Cancer
Himanshu Arora, Ph.D., oncology and urology researcher at Sylvester Comprehensive Cancer Center and Desai Sethi Urology Institute, both part of the University of Miami Miller School of Medicine, has…
New Strategies For Tackling Triple-Negative Breast Cancer
Research at JAX has uncovered a molecular “fingerprint” that could lead to better outcomes for TNBC patients. JAX Associate Research Scientist Francesca Menghi wants oncologists…
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes
Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas, MD, Andrea Rivas,…
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention
Footnotes Data sharing: The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or…
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Overview Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects…
Scott R. MacKenzie Foundation awards $350,000 in support of two-year clinical trial
Diana Azzam, a researcher in the Robert Stempel College of Public Health & Social Work, will collaborate with Cleveland Clinic Florida on a study to…
Seeing science fiction become reality
As a child growing up in East Millinocket, Maine, Scott MacKenzie was a huge fan of science and science fiction. One of the first magazines…